MedTrace Logo

An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel

NCT05735652 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2025-05-30

Study results available
· View outcomes & findings →

Summary

This observational study aims to evaluate the safety and effectiveness of radiotherapy for subjects with localized T1-T2 prostate cancer in China who were injected with SpaceOAR Hydrogel, via collecting clinical data related to radiotherapy.

Conditions

Interventions

DEVICE

SpaceOAR Hydrogel

The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Nianzeng Xing, Doctor · Hospital Executive

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-03
Primary Completion
2024-04-30
Completion
2024-08-21

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05735652 on ClinicalTrials.gov